Spotlight: Dr. Robert Princenthal at RadNet

image 13


Did you know that prostate cancer is the second most common cancer in men? According to the American Cancer Society, one in eight men will be diagnosed with prostate cancer during his lifetime. Currently, prostate cancer is the second leading cause of cancer death in American men, and yet, success rates for prostate cancer are actually higher than many other types of cancer if detected and treated early.

Dr. Robert Princenthal is a board-certified radiologist with more than 25 years of experience, and he has seen first-hand how accurate and early diagnosis of cancer can make a tremendous difference in patient outcomes. As medical director for RadNet’s Prostate MRI Program, Dr. Princenthal has been instrumental in establishing one of the first dedicated prostate programs in a radiology practice in the United States. This program includes some of the most advanced cancer-detecting technologies, including prostate MRI.

“Men need to learn how to fight like women,” Dr. Princenthal says. “Women have become empowered to improve the way breast cancer care is provided. The parallels between prostate cancer in men and breast cancer in women are remarkably similar.”

Under the stewardship of Dr. Princenthal and his co-director, Dr. Martin Cohen, the RadNet Prostate Program has performed more prostate MRI exams than any group in the country, with a level of accuracy that meets or exceeds top academic centers worldwide.

What is essential for men is what Dr. Princenthal calls the “man-o-gram,” or as he explains, “prostate MRI plus PSA screening, in order to optimize early detection.”

In addition to providing an extensive Prostate Program in California, RadNet has expanded to its centers in Phoenix, Arizona. Also under the guidance of Dr. Princenthal, RadNet launched its new TULSA-PRO treatment program for prostate disease at Liberty Pacific Advanced Imaging West Hills. TULSA-PRO, transurethral prostate ablation, is an incision-free therapy, completed under real-time MRI surveillance and is designed to provide a customizable, predictable, radiation-free thermal ultrasound ablation of a defined prostate volume. For more information visit us at

Dr. Princenthal reminds us that “the ability of evidence-based medicine to accurately screen, stage, and treat prostate cancer has never been better than right now.”